1. Home
  2. BTAI vs PBBK Comparison

BTAI vs PBBK Comparison

Compare BTAI & PBBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BTAI
  • PBBK
  • Stock Information
  • Founded
  • BTAI 2017
  • PBBK 1919
  • Country
  • BTAI United States
  • PBBK United States
  • Employees
  • BTAI N/A
  • PBBK N/A
  • Industry
  • BTAI Biotechnology: Pharmaceutical Preparations
  • PBBK Banks
  • Sector
  • BTAI Health Care
  • PBBK Finance
  • Exchange
  • BTAI Nasdaq
  • PBBK Nasdaq
  • Market Cap
  • BTAI 48.3M
  • PBBK 45.2M
  • IPO Year
  • BTAI 2018
  • PBBK N/A
  • Fundamental
  • Price
  • BTAI $2.07
  • PBBK $19.65
  • Analyst Decision
  • BTAI Buy
  • PBBK
  • Analyst Count
  • BTAI 5
  • PBBK 0
  • Target Price
  • BTAI $32.80
  • PBBK N/A
  • AVG Volume (30 Days)
  • BTAI 1.0M
  • PBBK 8.4K
  • Earning Date
  • BTAI 11-13-2025
  • PBBK 10-23-2025
  • Dividend Yield
  • BTAI N/A
  • PBBK N/A
  • EPS Growth
  • BTAI N/A
  • PBBK 52.99
  • EPS
  • BTAI N/A
  • PBBK 0.98
  • Revenue
  • BTAI $868,000.00
  • PBBK $13,918,000.00
  • Revenue This Year
  • BTAI N/A
  • PBBK N/A
  • Revenue Next Year
  • BTAI $614.78
  • PBBK N/A
  • P/E Ratio
  • BTAI N/A
  • PBBK $20.18
  • Revenue Growth
  • BTAI N/A
  • PBBK 17.20
  • 52 Week Low
  • BTAI $1.17
  • PBBK $14.05
  • 52 Week High
  • BTAI $13.28
  • PBBK $20.07
  • Technical
  • Relative Strength Index (RSI)
  • BTAI 34.40
  • PBBK 57.90
  • Support Level
  • BTAI $2.14
  • PBBK $19.50
  • Resistance Level
  • BTAI $2.46
  • PBBK $19.95
  • Average True Range (ATR)
  • BTAI 0.17
  • PBBK 0.24
  • MACD
  • BTAI 0.00
  • PBBK 0.07
  • Stochastic Oscillator
  • BTAI 2.64
  • PBBK 79.87

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

About PBBK PB Bankshares Inc.

PB Bankshares Inc follows a community bank model and provides multiple services to individuals and small to midsize businesses. Its business consists of attracting retail and commercial deposits from the general public in its market area and investing those deposits, together with funds generated from operations and borrowings, in commercial real estate loans, commercial and industrial loans, construction, home equity lines of credit and to a lesser extent, one- to four-family residential real estate loans and consumer loans.

Share on Social Networks: